Abstract
The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Current Drug Targets
Title: Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Volume: 10 Issue: 4
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Genovefa D. Kolovou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Abstract: The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios, Karagiannis Asterios, Kolovou D. Genovefa and Mikhailidis P. Dimitri, Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846425
DOI https://dx.doi.org/10.2174/138945009787846425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Lipid Metabolism and Relevant Disorders to Female Reproductive Health
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Epicardial Adipose Tissue As New Cardio-Metabolic Risk Marker and Potential Therapeutic Target in the Metabolic Syndrome
Current Pharmaceutical Design A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Understanding the Diverse Needs of Children Whose Parents Abuse Substances
Current Drug Abuse Reviews Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Oxidative Stress and Cardiac Remodeling: An Updated Edge
Current Cardiology Reviews AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Current Pharmaceutical Design Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents